These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38698606)

  • 21. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.
    Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H
    Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer.
    Chen J; Cao S; Situ B; Zhong J; Hu Y; Li S; Huang J; Xu J; Wu S; Lin J; Zhao Q; Cai Z; Zheng L; Wang Q
    J Exp Clin Cancer Res; 2018 Jun; 37(1):127. PubMed ID: 29954422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High Expression of BCAR1 by Circulating Tumor Cells and Tumor Tissues Is Predictive of a Poor Prognosis of Early-Stage Lung Adenocarcinoma Potentially Due to Regulation of Epithelial-Mesenchymal Transition.
    Jiang S; Mao C; Jiang B; Tan Q; Deng B
    Technol Cancer Res Treat; 2020; 19():1533033820983086. PubMed ID: 33334252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mesenchymal-Epithelial Transition and Circulating Tumor Cells in Small Cell Lung Cancer.
    Hamilton G; Rath B
    Adv Exp Med Biol; 2017; 994():229-245. PubMed ID: 28560677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
    Bian J; Yan K; Liu N; Xu X
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2621-2630. PubMed ID: 32661602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study.
    Morrow CJ; Trapani F; Metcalf RL; Bertolini G; Hodgkinson CL; Khandelwal G; Kelly P; Galvin M; Carter L; Simpson KL; Williamson S; Wirth C; Simms N; Frankliln L; Frese KK; Rothwell DG; Nonaka D; Miller CJ; Brady G; Blackhall FH; Dive C
    Ann Oncol; 2016 Jun; 27(6):1155-1160. PubMed ID: 27013395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients.
    Raimondi C; Gradilone A; Naso G; Vincenzi B; Petracca A; Nicolazzo C; Palazzo A; Saltarelli R; Spremberg F; Cortesi E; Gazzaniga P
    Breast Cancer Res Treat; 2011 Nov; 130(2):449-55. PubMed ID: 21298334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients.
    Yang L; Yan X; Chen J; Zhan Q; Hua Y; Xu S; Li Z; Wang Z; Dong Y; Zuo D; Xue M; Tang Y; Herschman HR; Lu S; Shi Q; Wei W
    Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epithelial‑mesenchymal transition phenotype of circulating tumor cells is associated with distant metastasis in patients with NSCLC.
    Zhang X; Wei L; Li J; Zheng J; Zhang S; Zhou J
    Mol Med Rep; 2019 Jan; 19(1):601-608. PubMed ID: 30483792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype.
    Hamilton G; Hochmair M; Rath B; Klameth L; Zeillinger R
    Cell Adh Migr; 2016 Jul; 10(4):360-7. PubMed ID: 26919626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A microfluidic device for differential capture of heterogeneous rare tumor cells with epithelial and mesenchymal phenotypes.
    Wang X; Deng L; Gjertsen BT
    Anal Chim Acta; 2020 Sep; 1129():1-11. PubMed ID: 32891378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research.
    Grover PK; Cummins AG; Price TJ; Roberts-Thomson IC; Hardingham JE
    Ann Oncol; 2014 Aug; 25(8):1506-16. PubMed ID: 24651410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer.
    Zhao R; Cai Z; Li S; Cheng Y; Gao H; Liu F; Wu S; Liu S; Dong Y; Zheng L; Zhang W; Wu X; Yao X
    Oncotarget; 2017 Feb; 8(6):9293-9302. PubMed ID: 28030836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
    Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
    Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1.
    Schehr JL; Schultz ZD; Warrick JW; Guckenberger DJ; Pezzi HM; Sperger JM; Heninger E; Saeed A; Leal T; Mattox K; Traynor AM; Campbell TC; Berry SM; Beebe DJ; Lang JM
    PLoS One; 2016; 11(7):e0159397. PubMed ID: 27459545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
    Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
    World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma.
    Sun YF; Guo W; Xu Y; Shi YH; Gong ZJ; Ji Y; Du M; Zhang X; Hu B; Huang A; Chen GG; Lai PBS; Cao Y; Qiu SJ; Zhou J; Yang XR; Fan J
    Clin Cancer Res; 2018 Feb; 24(3):547-559. PubMed ID: 29070526
    [No Abstract]   [Full Text] [Related]  

  • 38. Epithelial-mesenchymal transition status of circulating tumor cells in breast cancer and its clinical relevance.
    Zhou J; Zhu X; Wu S; Guo J; Zhang K; Xu C; Chen H; Jin Y; Sun Y; Zheng S; Chen Y
    Cancer Biol Med; 2020 Feb; 17(1):169-180. PubMed ID: 32296584
    [No Abstract]   [Full Text] [Related]  

  • 39. Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the clinical stages and cancer metastasis in hepatocellular carcinoma patients.
    Chen J; Cao SW; Cai Z; Zheng L; Wang Q
    Cancer Biomark; 2017 Dec; 20(4):487-498. PubMed ID: 28869439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.